The Bombay High Court has criticized the Food and Drug Administration (FDA) for violating principles of natural justice while revoking a Pune-based pharmaceutical company's licence. The FDA has now agreed to withdraw its order.
The Bombay High Court on Saturday issued a stern reprimand to the Food and Drug Administration (FDA) regarding its decision to revoke the drug sale licence of a Pune-based company. The bench, comprising Acting Chief Justice Ravindra Ghuge and Justice Gautam Ankhad, observed that the authority had acted in direct contravention of the principles of natural justice.
The legal battle began when Cipla Pharma and Life Sciences Limited challenged an FDA order dated August 27, which cancelled the licences for its carry and forwarding unit located at Vadki, Pune. The FDA's initial action was predicated on allegations of unauthorized text on the packaging of the drug 'Rectin Plus' and deficiencies in purchase-sale records and storage protocols.
The Procedural Lapse
During the proceedings, senior counsel Abad Ponda, representing the company, emphasized that the FDA's order did not raise any concerns regarding the safety, quality, or efficacy of the products. A critical point of contention was the timing of the communication: the FDA had sent an email on August 26—a public holiday—demanding the company appear for a hearing on that very same day.
When the company requested an adjournment due to the holiday, the FDA proceeded to pass the revocation order without granting a hearing. The court questioned the logic of the authority, noting that while the government frequently seeks adjournments citing holidays, it expected a private entity to comply with a same-day hearing request sent during a public holiday.
Why This Matters
BozokMedia analysis shows that administrative overreach by regulatory bodies can create significant instability within the pharmaceutical sector. When agencies bypass established legal procedures, it undermines the trust between the industry and the regulators, potentially leading to prolonged legal battles and economic disruption.
"You are doing commendable work, but now you are acting beyond your limits," the High Court remarked to the FDA.
The court noted that this was not an isolated incident of procedural misconduct by the FDA. Consequently, the FDA informed the bench that it would withdraw the revocation order and instead issue a fresh show-cause notice, allowing the company to present its defense before a final decision is made.
Frequently Asked Questions
1. What was the specific reason for the FDA's action against Cipla Pharma?
The FDA cited unauthorized packaging text on 'Rectin Plus' and discrepancies in drug storage and purchase records.
2. How did the High Court respond to the FDA's conduct?
The court slammed the FDA for ignoring natural justice and failing to provide a fair hearing, particularly by issuing notices on public holidays.
